You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

Diabetic Foot & Ankle Care, Peripheral Neuropathy-Neurological Evaluation

Percentage of patients aged 18 years and older with a diagnosis of diabetes mellitus who had a neurological examination of their lower extremities within 12 months.

Date Reviewed: November 19, 2017

Measure Info

MIPS 126NQF 0417CMS 126NQF Endorsed
Measure Type: 
Measure Steward: 
American Podiatric Medical Association
Clinical Topic Area: 

Care Setting: 
Data Source: 
Paper Medical Records

ACP does not support QPP measure 126: “Diabetic Foot & Ankle Care, Peripheral Neuropathy – Neurological Evaluation.” This measure has several issues. First, the measure developer cites a 44% performance gap based on data from the 2012 PQRS reporting year. However, this data only represents clinicians who chose to report on the measure and may inaccurately represent nation-wide performance levels. Second there is insufficient evidence to support a dedicated monofilament examination or the need to repeat the exam once the patient produces negative examination results. Clinical trials have proven the effectiveness of additional neurological assessment tools in diagnosing neurological deficits in diabetic patients. The numerator should specify the utilization of neurological assessment tools that are equally as effective as the mono filament in diagnosing neurological deficits in diabetic patients. Third, there is a lack of highquality evidence to suggest that regular, comprehensive full lower extremity neurological examinations in the primary care setting improves outcomes for asymptomatic patients. Therefore, while this measure represents good clinical care, quality improvement programs should not implement this measure to assess the performance quality of individual clinicians. While we note several issues with this measure, the measure specifications do include appropriate exclusion criteria for patients with previously documented loss of protective sensation, bilateral amputees, and patients with clinical conditions that prohibit accurate response to a neurological exam (e.g., dementia, Alzheimer’s).